公开(公告)号：WO2014186622A3

公开(公告)日：2015-01-08

申请号：PCT/US2014038267

申请日：2014-05-15

Applicant: ANNEXON INC ,  UNIV GLASGOW

Inventor： ROSENTHAL ARNON ,  LEVITEN MICHAEL ,  WILLISON HUGH J ,  MCGONIGAL RHONA

IPC: A61K39/395

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K16/40 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6854

Abstract: This invention relates generally to methods of treatment for Guillain-Barre' Syndrome (GBS) and, more specifically, to methods involving the inhibition of the classical pathway of complement activation. Certain aspects of the present disclosure are directed to methods of treating Guillain-Barre' syndrome (GBS) that include inhibiting the classical pathway of complement activation by neutralizing the complement factors C1q, C1r, or C1s, e.g., through the administration of antibodies, such as monoclonal, chimeric, humanized antibodies, antibody fragments, etc., which bind to one or more of these complement factors.

Abstract translation: 本发明一般涉及吉兰巴利综合征（GBS）的治疗方法，更具体地涉及涉及抑制补体活化的经典途径的方法。 本公开的某些方面涉及治疗吉兰巴利综合征（GBS）的方法，其包括通过中和补体因子C1q，C1r或C1s来抑制补体活化的经典途径，例如通过施用抗体，例如 作为与这些补体因子中的一种或多种结合的单克隆，嵌合，人源化抗体，抗体片段等。

公开(公告)号：WO2012120306A2

公开(公告)日：2012-09-13

申请号：PCT/GB2012050519

申请日：2012-03-08

Applicant: UNIV GLASGOW ,  HOLMES BARRY MICHAEL ,  HUTCHINGS DAVID CRICHTON ,  KELLY ANTHONY EDWARD ,  MARSH JOHN HAIG

Inventor： HOLMES BARRY MICHAEL ,  HUTCHINGS DAVID CRICHTON ,  KELLY ANTHONY EDWARD ,  MARSH JOHN HAIG

IPC: G02F1/035 ,  G02F1/377 ,  H01S5/026

CPC classification number: G02F1/035 ,  B82Y20/00 ,  G02B6/105 ,  G02F1/01708 ,  G02F1/377 ,  G02F2001/0142 ,  H01S5/0265 ,  H01S5/06251 ,  H01S2301/14 ,  H04N9/3161

Abstract: A polarisation control device having a polarisation converter in a first section of optical waveguide with a gradually varying asymmetrical cross-sectional (transverse) profile and an active phase shifter in a second section of optical waveguide whose birefringence is adjustable by a relative phase controller. The polarisation converter converts an orthogonal fundamental mode (TE or TM) into a hybridised signal present in the active phase shifter. The first and second sections of waveguide are joined to one another to form a single continuous waveguide, which can significantly reduce interfacial reflections. The invention teaches the introduction of a selectable degree of asymmetry to a section of planar optical waveguide after growth of that waveguide to form the polarisation converter. This feature enables the use of lower efficiency mode convertors to give far greater control over fabrication tolerances, leading to increased yield.

Abstract translation: 一种偏振控制装置，其具有在光波导的第一部分中具有逐渐变化的不对称横截面（横向）轮廓的偏振转换器和在相对相位控制器中双折射可由其调节的光波导的第二部分中的有源移相器。 偏振转换器将正交基模（TE或TM）转换为存在于有源移相器中的杂化信号。 波导的第一和第二部分彼此连接以形成单个连续波导，这可以显着减少界面反射。 本发明教导了在该波导的生长以形成偏振转换器之后，向平面光波导的一部分引入可选择的不对称程度。 该特征使得能够使用较低效率模式转换器对制造公差进行更大的控制，导致增加的产量。

公开(公告)号：WO2012085551A2

公开(公告)日：2012-06-28

申请号：PCT/GB2011052522

申请日：2011-12-20

Applicant: DOOSAN POWER SYSTEMS LTD ,  UNIV GLASGOW ,  KNOX ANDREW RAMSAY ,  MCCULLOCH EUAN ,  SIVITER JONATHAN

Inventor： KNOX ANDREW RAMSAY ,  MCCULLOCH EUAN ,  SIVITER JONATHAN

IPC: F01K17/00 ,  F22D1/18 ,  H01L35/00

CPC classification number: F01K17/005 ,  F22D1/18 ,  H01L35/30

Abstract: The present disclosure relates to condensers for use in condensing a working fluid in a thermal cycle apparatus prior to its re-entry into a working fluid line and onto a boiler, the condenser including a heat exchanger with a cold surface portion and a hot surface portion, the cold surface portion being disposed within a condensing chamber of the condenser, and the hot surface portion being deployed such that, in use, it transfers heat to condensed working fluid in a working fluid line prior to said condensed working fluid entering a boiler. It also covers thermal power stations and thermal cycles using such an apparatus, methods of improving thermal power stations and thermal cycles using such an apparatus. A temperature sink is also provided, which may be used in the condenser, other thermal power stations and thermal cycles using such an apparatus.

Abstract translation: 本公开涉及用于在热循环装置中重新进入工作流体管线和锅炉之前冷凝工作流体的冷凝器，该冷凝器包括具有冷表面部分和热表面部分的热交换器 冷表面部分设置在冷凝器的冷凝室内，并且热表面部分被展开，使得在使用中，热表面部分在所述冷凝的工作流体进入锅炉之前将热量传递到工作流体管线中的冷凝工作流体。 它还包括使用这种装置的火力发电站和热循环，使用这种装置改进火力发电站和热循环的方法。 还提供了一种温度传感器，其可用于冷凝器，其他热电站和使用这种装置的热循环。

公开(公告)号：WO2010131193A8

公开(公告)日：2011-12-08

申请号：PCT/IB2010052069

申请日：2010-05-11

Applicant: KONINKL PHILIPS ELECTRONICS NV ,  UNIV GLASGOW ,  HOFFMANN RALF ,  HOUSLAY MILES D ,  HENDERSON DAVID J P

Inventor： HOFFMANN RALF ,  HOUSLAY MILES D ,  HENDERSON DAVID J P

IPC: C12Q1/68 ,  C12N9/16 ,  C12N15/11 ,  C12Q1/44 ,  G01N33/574

CPC classification number: C12N15/1137 ,  C12N9/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  G01N33/57434 ,  G01N2800/52

Abstract: The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer.

Abstract translation: 本发明涉及用作前列腺癌标志物的磷酸二酯酶9A（PDE9A），以及使用PDE9A作为诊断，检测，监测或预测前列腺癌或前列腺癌进展的标志物。 本发明还涉及用于诊断，检测，监测或预测前列腺癌或前列腺癌进展的组合物，相应的方法和免疫测定，用于诊断，监测或预测激素抵抗性前列腺癌与激素敏感前列腺的方法 癌症，相应的免疫测定，数据采集方法，用于诊断，检测，监测或预测前列腺癌的免疫测定或前列腺癌的进展，鉴定个体对前列腺癌治疗的资格的方法，用于分层个体的免疫测定 或患有前列腺癌疾病的个体的群体，用于对患有前列腺癌的个体进行分层的免疫测定。 本发明进一步设想药物组合物及其用于治疗前列腺癌，特别是激素抗性前列腺癌的用途。

公开(公告)号：WO2010142999A2

公开(公告)日：2010-12-16

申请号：PCT/GB2010050983

申请日：2010-06-11

Applicant: UNIV GLASGOW ,  PUGH JOHN R ,  MCGLINCHEY DONALD ,  KNIGHT ELIZABETH A ,  MCKENNA PAUL ,  ZHENG YINGNA ,  LIU QIANG

Inventor： PUGH JOHN R ,  MCGLINCHEY DONALD ,  KNIGHT ELIZABETH A ,  MCKENNA PAUL ,  ZHENG YINGNA ,  LIU QIANG

IPC: G01F1/74

CPC classification number: G01F1/74 ,  G01F1/6847 ,  G01F1/688 ,  G01F1/6884 ,  G01F1/699

Abstract: A system and method for measuring mass flow of a non-gaseous phase (4) of material such as a solid particulate are described. The material flows through a conduit of which a section (14) is heated or cooled. One temperature sensor (6) is provided upstream of this section and at least another temperature sensor (7, 8) is provided downstream of it. These temperature sensors are adapted to measure the temperature of material in the non-gaseous phase directly. The section is heated or cooled for a first period of time and then neither heated nor cooled for a second period. A third temperature sensor (10) is provided in good thermal contact with the heated or cooled section - this temperature sensor. The temperature sensors measure the temperature of the non-gaseous phase of the material flowing the conduit in at least the second period of time. The mass flow of the non-gaseous phase of the material is calculated from the measurements of temperature.

Abstract translation: 描述了用于测量诸如固体颗粒的材料的非气相（4）的质量流量的系统和方法。 材料流过其中加热或冷却部分（14）的导管。 一个温度传感器（6）设置在该部分的上游，并且至少另一个温度传感器（7,8）设置在其下游。 这些温度传感器适于直接测量非气相物质的温度。 将该部分加热或冷却第一个时间段，然后不加热或冷却第二个时间段。 第三温度传感器（10）与被加热或冷却的部分（该温度传感器）具有良好的热接触。 温度传感器至少在第二段时间内测量流过导管的材料的非气相的温度。 材料的非气相的质量流量根据温度的测量值计算。

公开(公告)号：WO2010023442A3

公开(公告)日：2010-08-26

申请号：PCT/GB2009002071

申请日：2009-08-25

Applicant: UNIV GLASGOW ,  WEAVER JONATHAN MARK RALPH ,  DOBSON PHILLIP STEPHEN ,  BURT DAVID PAUL ,  THOMS STEPHEN ,  DOCHERTY KEVIN EDWARD ,  ZHANG YUAN

Inventor： WEAVER JONATHAN MARK RALPH ,  DOBSON PHILLIP STEPHEN ,  BURT DAVID PAUL ,  THOMS STEPHEN ,  DOCHERTY KEVIN EDWARD ,  ZHANG YUAN

IPC: G01D5/26 ,  G01D11/00

CPC classification number: G01D5/266 ,  G01D5/38 ,  G01D11/00 ,  G01J9/0246 ,  G01J2009/0234 ,  G01N21/45 ,  G03H1/0005

Abstract: Various uses of visible light interference patterns are provided. Suitable interference patterns are those formed by diffraction from patterns of apertures. Typical uses disclosed herein relate to spatial metrology, such as a translational and/or angular position determination system. Further uses include the analysis of properties of the light itself (such as the determination of the wavelength of the electromagnetic radiation). Still further uses include the analysis of one or more properties (e.g. refractive index) of the matter through which the light passes. Part of the interference pattern is captured at a pixellated detector, such as a CCD chip, and the captured pattern compared with a calculated pattern. Very precise measurements of the spacing between maxima is possible, thus allowing very precise measurements of position of the detector in the interference pattern.

Abstract translation: 提供了可见光干涉图案的各种用途。 合适的干涉图案是由孔径图案衍射形成的图案。 这里公开的典型用途涉及空间度量，例如平移和/或角度位置确定系统。 其他用途包括光本身性质的分析（例如确定电磁辐射的波长）。 另外的用途包括分析光通过的物质的一种或多种性质（例如折射率）。 部分干涉图案在诸如CCD芯片的像素化检测器处捕获，并且捕获的图案与计算出的图案相比较。 可以非常精确地测量最大值之间的间距，从而可以非常精确地测量干涉条纹中探测器的位置。

公开(公告)号：WO2006013388A3

公开(公告)日：2006-08-24

申请号：PCT/GB2005003097

申请日：2005-08-05

Applicant: UNIV GLASGOW ,  CANCER REC TECH LTD ,  CUSHLEY WILLIAM ,  BORLAND GILLIAN ,  OZANNE BRADFORD

Inventor： CUSHLEY WILLIAM ,  BORLAND GILLIAN ,  OZANNE BRADFORD

IPC: A61K38/02 ,  A01K67/027 ,  A61K38/00 ,  A61K38/08 ,  A61P29/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/78 ,  C12N5/16 ,  C12N15/12 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  A61K38/00 ,  C07K14/7056 ,  C12Q2600/136

Abstract: It is disclosed that the avß5 integrin mediates the proliferative signal provided by CD23 to pre-B cells. The region of CD23 which interacts with avß5 has been defined, and found to interact with a site on the integrin distinct from that which binds RGD. The invention provides methods for disrupting the interaction between CD23 and avß5 and methods of screening for chemical entities capable of disrupting this interaction.

Abstract translation: 据披露，avβ5整联蛋白介导由CD23提供的增殖信号至前B细胞。 与avß5相互作用的CD23区域已被定义，并且发现与整合蛋白上的一个位点不同于与RGD结合的位点相互作用。 本发明提供了破坏CD23和avβ5之间相互作用的方法以及筛选能够破坏这种相互作用的化学实体的方法。

公开(公告)号：WO2004062560A3

公开(公告)日：2004-10-28

申请号：PCT/GB2004000044

申请日：2004-01-09

Applicant: UNIV STRATHCLYDE ,  UNIV GLASGOW ,  MOORE BARRY DOUGLAS ,  PARKER MARIE CLAIRE ,  PARTRIDGE JOHANN ,  VOS JAN ,  KREINER MICHAELA MARIA ,  STEVENS HOWARD NORMAN ERNEST ,  FLORES MARIA VICTORIA ,  ROSS ALISTAIR

Inventor： MOORE BARRY DOUGLAS ,  PARKER MARIE CLAIRE ,  PARTRIDGE JOHANN ,  VOS JAN ,  KREINER MICHAELA MARIA ,  STEVENS HOWARD NORMAN ERNEST ,  FLORES MARIA VICTORIA ,  ROSS ALISTAIR

IPC: A61K20060101 ,  A61K6/00 ,  A61K9/14 ,  A61K9/16 ,  A61K38/00 ,  A61K38/28 ,  A61K39/05

CPC classification number: A61K9/1682 ,  A61K9/145 ,  A61K9/1617 ,  A61K9/1623 ,  A61K38/28 ,  A61K39/05 ,  A61K2039/55555

Abstract: This invention relates to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule. The invention also relates to methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule.

Abstract translation: 本发明涉及包含具有基本上非吸湿性内晶核的颗粒和包含至少一种生物活性分子的外涂层的药物制剂。 本发明还涉及形成包含基本上非吸湿性内晶核和包含至少一种生物活性分子的外涂层的颗粒的方法。

公开(公告)号：WO03024474A3

公开(公告)日：2003-08-21

申请号：PCT/GB0204310

申请日：2002-09-20

Applicant: UNIV STRATHCLYDE ,  UNIV GLASGOW ,  HARNETT WILLIAM ,  HARNETT MARGARET B ,  MCINNES IAIN

Inventor： HARNETT WILLIAM ,  HARNETT MARGARET B ,  MCINNES IAIN

IPC: A61K38/17 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P11/00 ,  A61P17/04 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  C07K14/435 ,  A61K38/14 ,  A61K39/00

CPC classification number: A61K38/17 ,  C07K14/4354

Abstract: This invention relates to the use of a phosphorylcholine-containing glycoprotein in the treatment or prophylaxis of diseases associated with inflammation. In particular, the present invention relates to the use of ES-62 for the treatment or prophylaxis of autoimmune diseases associated with abnormal inflammation, such as rheumatoid arthritis.

Abstract translation: 本发明涉及含有磷酸胆碱的糖蛋白在治疗或预防与炎症相关的疾病中的用途。 具体而言，本发明涉及ES-62用于治疗或预防与异常炎症相关的自身免疫性疾病如类风湿性关节炎的用途。

公开(公告)号：WO03038487A2

公开(公告)日：2003-05-08

申请号：PCT/GB0204993

申请日：2002-10-31

Applicant: UNIV GLASGOW ,  CENTRE NAT RECH SCIENT ,  FRANCE TELECOM ,  MARSH JOHN HAIG ,  BRYCE ANN CATRINA ,  QUI BOCANG ,  RAO ELCHURI ,  THEYS BERTRAND ,  HEYMES YVON

Inventor： MARSH JOHN HAIG ,  BRYCE ANN CATRINA ,  QUI BOCANG ,  RAO ELCHURI ,  THEYS BERTRAND ,  HEYMES YVON

IPC: G02B6/12 ,  G02B6/136 ,  H01L21/18 ,  H01L21/322 ,  H01L21/324 ,  H01S5/34 ,  G02B6/00

CPC classification number: B82Y20/00 ,  G02B6/136 ,  G02B2006/12097 ,  G02B2006/12128 ,  H01L21/182 ,  H01L21/3228 ,  H01L21/3245 ,  H01S5/3414

Abstract: There is disclosed an improved method of manufacturing optical devices (115a; 115b). A requirement for photonic Integrated Circuits is the realization of low-loss optical waveguides. Optical absorption by Fundamental Edge Absorption (FEA) can be reduced by using Quantum Well Intermixing (QWI) to widen the band-gap of passive waveguides. However, impurities and/or and structural defects responsible for (QWI) are all usually charged and have free electrons or holes associated with them, giving rise to optical absorption by Free-Carrier Absorption (FCA). Accordingly, the invention provides a method of manufacturing an optical device (115a; 115b), a device body portion (5a; 5b) from which the device (115a; l15b) is to be made including a Quantum Well (QW) structure (25a; 25b). )the method including the steps of: intermixing at least part of the Quantum well (QW) structure (25a; 25b); and passivating at least some dopants and/or point defects within at least a portion of the device body portion (5a; 5b). By "passivating" is meant neutralizing the electronic activity of the dopants.

Abstract translation: 公开了一种制造光学器件（115a; 115b）的改进方法。 对光子集成电路的要求是实现低损耗光波导。 通过使用量子阱混合（QWI）来拓宽无源波导的带隙，可以减少基础边缘吸收（FEA）的光吸收。 然而，负责（QWI）的杂质和/或结构缺陷通常都是带电的并且具有与其相关的自由电子或空穴，从而通过自由载流子吸收（FCA）引起光吸收。 因此，本发明提供了一种制造光学装置（115a; 115b）的方法，包括量子阱（QW）结构（25a）的制造装置（115a; 115b）的装置主体部分（5a; 5b） ; 25b）。 ）该方法包括以下步骤：混合量子阱（QW）结构（25a; 25b）的至少一部分; 以及钝化所述器件主体部分（5a; 5b）的至少一部分内的至少一些掺杂剂和/或点缺陷。 “钝化”是指中和掺杂剂的电子活性。